BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion in an all-cash transaction that the companies expect to close in the second quarter of 2026. The deal transfers two marketed rare‑disease therapies — the oral Fabry drug Galafold and the two-component Pompe therapy Pombiliti/Opfolda — plus U.S. rights to a Phase III kidney candidate, DMX‑200. Boards of both companies approved the transaction and BioMarin said the assets will bolster its commercial footprint in enzyme-replacement and small‑molecule rare‑disease treatments. The acquisition is being positioned as a strategic move to add near-term revenue and late‑stage pipeline depth while the company pursues additional bolt‑on deals. Market reaction and analyst commentary noted the premium paid and the immediate revenue contribution from Amicus’ marketed products. BioMarin’s management highlighted expected cost synergies and portfolio scale as the rationale for the purchase. Sources: company filings and industry reporting (BioCentury, STAT, MedCity News).